Carla Baan, PhD, University Hospital Rotterdam, Rotterdam, The Netherlands
Edward Cantu III, MD, MSCE, University of Pennsylvania, Philadelphia, PA, USA
Daniel Chambers, MBBS, MRCP, FRACP, MD, The Prince Charles Hospital, Brisbane, Australia
Esme Dijke, PhD, University of Alberta, Edmonton, Canada
Eric Epailly, MD, Centre Hospitalier de l’Université de Strasbourg, Strasbourg, France
Christine Falk, PhD, Hannover Medical School, Hannover, Germany
Andrew Gelman, PhD, Washington University, St. Louis, MO, USA
John Greenland, MD, PhD, University of California San Francisco, San Francisco, CA, USA
Stephen Juvet, MD, PhD, University of Toronto, Toronto, Canada
Joren Madsen, MD, DPhil, Massachusetts General Hospital, Boston, MA, USA
Tereza Martinu, MD, Toronto General Hospital/UHN, Toronto, Canada
Federica Meloni, MD, PhD, Policlinico San Matteo, Pavia, Italy
Ciara Shaver, MD, PhD, Vanderbilt University Medical Center, Nashville, TN, USA
Simon Urschel, MD, University of Alberta, Edmonton, Canada
Stijn Verleden, PhD, KU Leuven, Leuven, Belgium
Glen Westall, MD, PhD, Alfred Hospital, Melbourne, Australia

The educational goals of this activity are to provide a concise review of basic concepts in transplant-related immunology and molecular biology, to define and promote the clinical relevance of basic science and translational research related to heart and lung transplantation, and to encourage interaction between basic scientists, translational researchers and clinicians.

This course is primarily designed to be of benefit for clinicians, allied health professionals, and researchers who are in the early stages of their careers, or who are in training and/or are part of a new program, or desire an update on the current state of the field. The information presented covers core competencies and is intended to provide a strong foundation of the overarching principles pertinent to basic science and translational research in thoracic transplantation, rather than as a detailed update for those who are already proficient experts in the field.

At the conclusion of this meeting, participants will have improved competence and professional performance in their abilities to:
 

1. Discuss basic concepts in transplant-related immunology and molecular biology;
2. Recognize key analytical techniques and models used in transplantation research;
3. Understand basic mechanisms of immunosuppression;
4. Recognize key contributions from basic research in transplantation that improved clinical outcomes inheart and lung transplantation;
5. Recognize how clinical questions may inspire basic research;
6. Improve effective communication between research scientists and clinicians and health careprofessionals.

Physicians
Accreditation Statement – The International Society for Heart and Lung Transplantation (ISHLT) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement – ISHLT designates this live activity for a maximum of 7.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses and Pharmacists
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and ISHLT. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statement – Amedco LLC designates this live activity for a maximum of 7.50 contact hours for nurses and 3.0 knowledge-based contact hours for pharmacists. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Current guidelines state that participants in CME activities must be made aware of any affiliation or financial interest that may affect the program content or a speaker’s presentation. Planners, Faculty and Chairs participating in this meeting are required to disclose to the program audience any real or apparent conflict(s) of interest related to the content of their presentations or service as Chair/Planner. These disclosures will be distributed at the meeting. Additionally, all speakers have been asked to verbally disclose at the start of their presentation if a product they are discussing is not labeled for the use under discussion or is still investigational.